Candel Therapeutics (CADL) Other Non-Current Liabilities (2020 - 2023)
Historic Other Non-Current Liabilities for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $433000.0.
- Candel Therapeutics' Other Non-Current Liabilities fell 9063.99% to $433000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $433000.0, marking a year-over-year decrease of 9063.99%. This contributed to the annual value of $1.9 million for FY2022, which is 8968.88% down from last year.
- Candel Therapeutics' Other Non-Current Liabilities amounted to $433000.0 in Q3 2023, which was down 9063.99% from $1.0 million recorded in Q2 2023.
- In the past 5 years, Candel Therapeutics' Other Non-Current Liabilities ranged from a high of $27.4 million in Q3 2021 and a low of $433000.0 during Q3 2023
- Over the past 4 years, Candel Therapeutics' median Other Non-Current Liabilities value was $5.0 million (recorded in 2022), while the average stood at $8.7 million.
- As far as peak fluctuations go, Candel Therapeutics' Other Non-Current Liabilities soared by 16719.37% in 2021, and later crashed by 9063.99% in 2023.
- Quarter analysis of 4 years shows Candel Therapeutics' Other Non-Current Liabilities stood at $6.8 million in 2020, then surged by 167.19% to $18.3 million in 2021, then plummeted by 89.69% to $1.9 million in 2022, then crashed by 76.99% to $433000.0 in 2023.
- Its Other Non-Current Liabilities stands at $433000.0 for Q3 2023, versus $1.0 million for Q2 2023 and $1.2 million for Q1 2023.